Course Catalog
Browse our full catalog of continuing education courses and events
Browse Courses & Events
Join Us at The Ophthalmology Meeting This October in New Orleans
October 9, 2026
Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice
June 15, 2026
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society
Seth A. Wander, MD, PhD; Kate Baxstrom, MD
Rapid Reviews in Retina™: Emerging Updates from Winter 2026 – Addressing the Wealth of New Data in Treatments for nAMD, DME, and RVO
Judy E. Kim, MD, FARVO, FASRS; Prethy Rao, MD, MPH, FACS
Oncology Town Hall: Updates from Berlin: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us
May 27, 2026
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society
Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD
Cases and Conversations™: Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders
June 23, 2026
AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD
September 13, 2026
Oncology Town Hall: Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us
June 8, 2026
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina
Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana
Yan Ji, MD; Neil M. Iyengar, MD
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington
Alison K. Conlin, MD; Neil M. Iyengar, MD
Show Me the Data®: From Mutation to Action — KRAS as a Therapeutic Target in PDAC
E. Gabriela Chiorean, MD; Tanios S. Bekaii-Saab, MD; Mitesh Borad, MD; Christopher Lieu, MD
Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice Society
Seth A. Wander, MD, PhD; Kamel Abou Hussein, MD
Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, Maintenance, and Beyond! – Arizona
Naval G. Daver, MD; Matthew Ulrickson, MD
Clinical Crossroads™: Delayed Identification of Hypercortisolism – What Are the Risks?
Yehuda Handelsman, MD, FACP, FNLA, FASPC, FAHA, MACE
Optimizing HER2 Testing in Gastroesophageal Adenocarcinoma: Laying the Foundation for Targeted Therapy
Yelena Y. Janjigian, MD; Michal F. Segal, BSN, OCN
Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy
Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Ashley S. Margol, MD, MS
Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer
Ursula A. Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; Ritu Salani, MD, MBA; Oladapo Yeku, MD, P...
Cases and Conversations™: Redefining Treatment Pathways in Low-Grade Serous Ovarian Cancer
Rachel N. Grisham, MD; David M. Gershenson, MD; Ursula Matulonis, MD; David M. O’Malley, MD
11th Annual School of Gastrointestinal Oncology®
E. Gabriela Chiorean, MD; Anthony El-Khoueiry, MD
Live Tumor Board: Multidisciplinary Strategies to Prevent and Manage ADC-Associated Pulmonary Toxicities in Ovarian Cancer
Kathleen N. Moore, MD, MS, FASCO; Rachel N. Grisham, MD; Rohit Gupta, MD; Maida Hafiz, MD
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Texas
Sheila Donnelly, MD; Virginia Kaklamani, MD, DSc
Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Minnesota
Neil M. Iyengar, MD; Kimberly Ku, MD
Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice
Eunice Wang, MD; Hetty Carraway, MD, MBA; Naval G. Daver, MD
Cases and Conversations™: Integrating PSMA-Directed Radioligand Therapy in Prostate Cancer Care: Recent Data and Evolving Strategies
Mary-Ellen Taplin, MD; Jeremie Calais, MD, PhD; Himanshu Nagar, MD, MS
Lupus Nephritis Postgame: Takeaways from our Expert Faculty
Shivani Garg, MD, PhD; Samir V. Parikh, MD, FASN
Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities
Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenov...
Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas
David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD; Jonathan Strosberg, MD
19th Annual New York GU Cancers Congress®
Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MD
A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes
4-Part Webinar Series
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, MBS
Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer
Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH
Burst CME Expert Illustrations & Commentaries™: Breaking Down DLL3-Targeting Immune Cell Effector Agents in SCLC
Jacob Sands, MD; Anne Chiang, MD, PhD
Collaborating Across the Continuum®: Tying the Threads: Screening, Referrals, and Optimized Treatments in MASLD/MASH
Nancy Reau, MD; Conan Tu, MD; Sonal Kumar, MD, MPH
Publication Review: Defining On-Treatment Remission in Plaque Psoriasis
April W. Armstrong, MD, MPH; Tina Bhutani-Jacques MD
Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies
John Kitchens, MD
Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer
Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry Shen, MD
How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients
Michael Levy, MD, PhD; Jeffrey L. Bennett, MD, PhD; Eoin P. Flanagan, MB, BCh
OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer
Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; Seth A. Wander, MD, PhD
Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer
Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, MBA, FACP